The safety of intravenous thrombolysis (IVT) in patients with acute ischemic stroke over the age of 80 is unclear. We hypothesized that patients over the age of 80 can be safely treated with IVT.
T he only approved treatment for acute ischemic stroke is intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator. 1 When administered within 4.5 hours of ischemic stroke onset, IVT improves functional outcomes at 3 months, is cost effective, and has an excellent safety profile. 1,2 A common exclusion criterion for IVT under 3 hours of onset is age over 80 years, 3 although the National Institute of Neurological Disorders tissue plasminogen activator trial did not include an age limit for inclusion and no age cutoff is mentioned in American Heart Association guidelines for patients treated under 3 hours of onset. 1 In contrast, IVT is not recommended for patients presenting between 3 and 4½ hours who are over 80 years of age, as they were excluded from the European Cooperative Acute Stroke Study III. 2 Several investigators have raised the concern that those over 80 years of age may derive less clinical benefit from IVT, or that their rate of hemorrhage is higher than in younger patients. [4] [5] [6] [7] In this study, we compared in-hospital mortality in patients over 80 years of age who arrived within 3 hours of onset on the basis of whether they received IVT; secondary outcomes included length of stay (LOS), symptomatic hemorrhage, and discharge disposition.
METHODS
Our data were drawn from the Specialized Program of Translational Research in Acute Stroke program at Columbia University Medical Center. We collected data on all patients who presented to the emergency room within 12 hours of stroke onset and who either consented to participate in a registry or trial, or were included by means of an institutional review board-approved waiver of consent. Our analysis was limited to those admitted between December 1, 2004 and June 30, 2010. We analyzed discharge outcomes for patients over the age of 80 who arrived at the emergency room within 3 hours of ischemic stroke onset. Clinical information obtained in all patients included socio-demographic variables (age, sex, and race-ethnicity), initial National Institutes of Health Stroke Scale (NIHSS), treatment with IVT, discharge disposition, LOS, mortality, and 24-hour neuro-imaging (magnetic resonance imaging or computer tomography). A computer tomography scan of the head was perormed and NIHSS scores were obtained for all patients 24 hours after IVT. Preadmission functional status was not available in a large proportion of patients. Symptomatic intracranial hemorrhage (sICH) was defined as any hemorrhage on neuro-imaging with an associated increase in the NIHSS of Z4. 8 The primary exposure of interest was IVT and our primary outcome measure was in-hospital mortality. Secondary outcomes of interest included discharge disposition (defined as discharge to home vs. all others), hospital LOS, and sICH.
Baseline demographics of those who were treated versus those not treated with IVT were compared using a 2-sided t test for continuous variables, and a w 2 test for categorical variables. Contingency tables and multivariable logistic regression was used to derive odds ratios (OR) and 95% confidence intervals (CI) for mortality and discharge disposition on the basis of IVT; models were adjusted for age, sex, race-ethnicity, and pretreatment NIHSS. We did not adjust for further variables given the small sample size to avoid overadjusting our models. To examine whether IVT influenced LOS, linear regression models were calculated in a similar manner. All analyses were carried out with SAS version 9.2 (Cary, NC).
RESULTS
The baseline demographics of the sample are presented in Table 1 . A total of 112 patients over the age of 80 presented within 3 hours of ischemic stroke onset (age range, 80 to 101 y), and 31 received IVT. The principal reasons for not administering IVT were rapidly improving deficit (n = 37) and/ or the inability to initiate treatment within 3 hours (n = 30). The median NIHSS score in all patients was 6 [interquartile range (IQR), 1 to 16] and was lower in those patients who were untreated (median, 4; IQR, 1 to 11) compared with those who were treated (median, 14; IQR, 8 to 22). There were no other differences in baseline demographics. Table 2 outlines the results comparing in-hospital outcomes among treated and untreated patients. There were 15 inhospital deaths among all patients, and 60 were not discharged home. In multivariable analyses, IVT (vs. no treatment) was not associated with an increased risk of in-hospital death (adjusted OR, 1.2; 95% CI, 0.3-4.3), and was associated with a trend towards disposition other than to home (adjusted OR, 2.9; 95% CI, 0.9-8.9). The mean LOS was 6.7 days and was 3.4 days longer in those treated with IVT. There was 1 symptomatic hemorrhage (3%) in the IVT-treated group.
DISCUSSION
In this sample of patients over the age of 80 who arrived at the emergency room within 3 hours, those who were treated with IVT did not have an increased risk of death compared with those not treated, and had an acceptably low hemorrhage rate. Our results add to the indirect evidence of the safety of IVT in patients over the age of 80, which in combination with clinical trial data, indicate that age should not be an exclusion criterion for treatment. Our findings are notable given that removal of an exclusion criterion of age over 80 years could increase the proportion of IVT-treated patients by close to 10%. 9 In our study, patients treated with IVT had more severe strokes, which was reflected in the longer LOS and a trend towards not being discharged home, and yet this did not translate to a higher risk of sICH or death. The reports regarding safety of IVT in octogenarians were likely driven by stroke severity and prestroke functional status, 5,10 as well as by selection of controls who were younger than 80 years. Older patients are more likely to have severe strokes because of the high prevalence of atrial fibrillation, and poor outcomes appear to be driven by in-hospital medical complications that could also affect LOS. [11] [12] [13] A more severe deficit would also make it less likely for a patient to be discharged home.
Our institution does not have formal criteria for excluding patients from IVT on the basis of age, although clinicians may look for other reasons not to treat patients in this age group. In keeping with this hypothesis, we found it noteworthy that a high proportion of participants over the age of 80 were not treated because of a mild or rapidly improving deficit. Others have noted that those over the age of 80 are less likely to have protocol violations when given IVT. 14 Our results differ from those of others, who report that treatment in those over the age of 80 is associated with poor outcomes. 4, 5, 11, [15] [16] [17] Our findings could be related to the choice of control group in that patients presenting under 3 hours over the age of 80 would be likely to have a poor outcome regardless of IVT.
Our study, however, has some important limitations. Our sample size was small, and therefore we cannot exclude the possibility that we were underpowered to detect a difference in mortality rates. We did not collect information on in-hospital complications, including pneumonia and other infections, or other markers of prestroke comorbidity. There is likely to be residual confounding related to stroke severity that we were not able to adjust for in our models. It is likely that prehospital functional status and stroke severity interact with age to influence outcome after IVT. 11 We did not carry out an efficacy study, which should include 90-day outcomes and a random assignment to IVT, and we can therefore not comment on long-term clinical efficacy in this age group. Nonetheless, previous analyses have shown that those over 80 years may benefit from treatment with IVT. 18, 19 A review of the Safe Implementation of Treatment in Stroke databasesInternational Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive (VISTA)-showed that age was a significant predictor of poor outcome, although older patients continued to receive a benefit from thrombolysis. 20 To show a more robust clinical benefit in those over the age of 80, registries and clinical trials will need to consider premorbid functional status, stroke severity, and meaningful clinical outcomes. Our analyses support that these patients can have an excellent safety profile, and therefore age over 80 should not be considered a contraindication for IVT.
